Sex differences in mortality risk profiles across the life course in metabolic dysfunction-associated steatotic liver disease: a machine learning analysis of the Canadian Longitudinal Study on Aging

Abstract Background Prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) are largely ‘one-size-fits-all’ and do not collectively account for sex differences and social determinants of health (SDoH). To address this gap, we trained and developed sex-specific machine learning models that incorporated SDoHs to examine important predictors of all-cause mortality among adults with MASLD. Methods Using the Canadian Longitudinal Study on Aging, MASLD was defined as the presence of hepatic steatosis, at least one cardiometabolic risk factor, and low levels of sex-specific alcohol consumption (females: < 140 g/week, males: < 210 g/week). Three machine learning models were examined in sex and age-specific subgroups (middle-age: 45–64 years vs. older age: $$\:\ge\:$$ 65 years). Based on the literature, expert input, and data availability, 25, clinical, sociodemographic, and lifestyle predictors capturing upstream, intermediate, or surrogate factors associated with MASLD progression and mortality were considered. The cohorts were split into 75% training and 25% testing, and 5-fold cross-validation was used for hyperparameter tuning. Evaluation was performed in the held-out test set using the Concordance index (C-Index), integrated Brier score (iBS), time-dependent area under the curve (AUC(t)), and visual calibration plots. Important predictors were described based on global importance and directionality of Shapley additive explanation values. Results Of 30,097 participants, we identified 8,429 with MASLD (35.3% female) followed for a median of 7.67 years (IQR: 6.84, 8.45), of which 631 (7.5%) died. Using a random survival forest model, all-cause mortality risk prediction demonstrated meaningful stratification across the follow-up period (Females: C-Index 0.73, iBS 0.032, mean AUC(t) 0.78; Males: C-Index 0.79, iBS 0.035, mean AUC(t) 0.82). Risk prediction profiles for females and males differed. Alongside clinical factors such as albumin and cardiometabolic multimorbidity, female risk was impacted by income, education, and lifestyle, particularly in middle-age. Comparatively, metabolic parameters such as waist circumference, blood pressure, albumin, and body mass index were important predictors for males. Conclusion Our findings describe how mortality risk prediction profiles for people with MASLD vary by sex and age. This highlights the potential value of integrating SDoHs into sex-specific prognostication, bridging social and precision medicine to enable more equitable, individualized risk prediction in MASLD.

Authors

Institutions

Publication Details

Journal
Biology of Sex Differences
Published
2026-10-05
DOI
https://doi.org/10.1186/s13293-026-00992-9
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Sex differences in mortality risk profiles across the life course in metabolic dysfunction-associated steatotic liver disease: a machine learning analysis of the Canadian Longitudinal Study on Aging

Sahar Saeed, Jennifer A. Flemming, Cindy Xin Wen, Keyur Patel et al.
Biology of Sex Differences
Liver Disease Diagnosis and Treatment
article

Sex differences in mortality risk profiles across the life course in metabolic dysfunction-associated steatotic liver disease: a machine learning analysis of the Canadian Longitudinal Study on Aging

Sahar Saeed, Jennifer A. Flemming, Cindy Xin Wen, Keyur Patel, Erica E. M. Moodie, Mark G. Swain, Giada Sebastiani, Jessica Burnside, Carmela Rapino, Alnoor Ramji, Wei Tu
article en

Abstract

Abstract Background Prognostic models for metabolic dysfunction-associated steatotic liver disease (MASLD) are largely ‘one-size-fits-all’ and do not collectively account for sex differences and social determinants of health (SDoH). To address this gap, we trained and developed sex-specific machine learning models that incorporated SDoHs to examine important predictors of all-cause mortality among adults with MASLD. Methods Using the Canadian Longitudinal Study on Aging, MASLD was defined as the presence of hepatic steatosis, at least one cardiometabolic risk factor, and low levels of sex-specific alcohol consumption (females: < 140 g/week, males: < 210 g/week). Three machine learning models were examined in sex and age-specific subgroups (middle-age: 45–64 years vs. older age: $$\:\ge\:$$ 65 years). Based on the literature, expert input, and data availability, 25, clinical, sociodemographic, and lifestyle predictors capturing upstream, intermediate, or surrogate factors associated with MASLD progression and mortality were considered. The cohorts were split into 75% training and 25% testing, and 5-fold cross-validation was used for hyperparameter tuning. Evaluation was performed in the held-out test set using the Concordance index (C-Index), integrated Brier score (iBS), time-dependent area under the curve (AUC(t)), and visual calibration plots. Important predictors were described based on global importance and directionality of Shapley additive explanation values. Results Of 30,097 participants, we identified 8,429 with MASLD (35.3% female) followed for a median of 7.67 years (IQR: 6.84, 8.45), of which 631 (7.5%) died. Using a random survival forest model, all-cause mortality risk prediction demonstrated meaningful stratification across the follow-up period (Females: C-Index 0.73, iBS 0.032, mean AUC(t) 0.78; Males: C-Index 0.79, iBS 0.035, mean AUC(t) 0.82). Risk prediction profiles for females and males differed. Alongside clinical factors such as albumin and cardiometabolic multimorbidity, female risk was impacted by income, education, and lifestyle, particularly in middle-age. Comparatively, metabolic parameters such as waist circumference, blood pressure, albumin, and body mass index were important predictors for males. Conclusion Our findings describe how mortality risk prediction profiles for people with MASLD vary by sex and age. This highlights the potential value of integrating SDoHs into sex-specific prognostication, bridging social and precision medicine to enable more equitable, individualized risk prediction in MASLD.

Biology of Sex Differences
University Health Network (CA), University of British Columbia (CA), University of Calgary (CA), Queen's University (CA), Canadian Cancer Trials Group (CA), McGill University (CA), Toronto Metropolitan University (CA)
Openalex Percentile: Top 11%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.